4Kawashima T,Murakami H,Kanamori T,et al.A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy[J].Gan To Kagaku Ryoho,2007,34(3):461-463.
5Gershenson DM.Irinotecan in epithelial ovarian cancer[J].Oncology(Huntingt),2002,16(5Supp15):29-31.
6Nishimura S,Tsuda H,Hashiguchi Y,et al.Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer:interim analysis[J].Int J Gynecol Cancer,2007,17(1):159-163.
7Matsumoto K,Katsumata N,Yamanaka Y,et al.The safety and efficacy of the weekly dosing of irinotecan for platinum-and taxanes-resistant epithelial ovarian cancer[J].Gynecol Oncol,2006,100(2):412-416.
8Sugiyama T,Ushijma K,Kamura T.New regimens for the treatment of gynecologic cancers[J].Gan To Kagaku Ryoho,2000,27(3):375-381.
9Nishio S,Sugiyama T,Shouji T,et al.Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum-and taxane-resistant epithelial ovarian cancer[J].Gynecol Oncol,2007,106(2):342-347.
10Limonti A,Gelibter A,Pavese I,et al.New approaches to prevent intestinal toxicity of irinotecan-based regimens[J].Cancer Treat Rev,2004,30(6):555-562.
